These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8983284)

  • 1. An increased loading dose of ondansetron: a north european, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2.
    Brock P; Brichard B; Rechnitzer C; Langeveld NE; Lanning M; Söderhäll S; Laurent C
    Eur J Cancer; 1996 Sep; 32A(10):1744-8. PubMed ID: 8983284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
    Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
    Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group.
    Needles B; Miranda E; Garcia Rodriguez FM; Diaz LB; Spector J; Craig J; Cohen G; Krasnow S; Brogden J; Ames M
    Support Care Cancer; 1999 Sep; 7(5):347-53. PubMed ID: 10483821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
    White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
    Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
    Fumoleau P; Giovannini M; Rolland F; Votan B; Paillarse JM
    Oral Oncol; 1997 Sep; 33(5):354-8. PubMed ID: 9415336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group.
    Davidson NG; Paska W; Van Belle S; Goedhals L; McQuade B; McRae J
    Oncology; 1997; 54(5):380-6. PubMed ID: 9260599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
    Ruktrirong J; Traivaree C; Monsereenusorn C; Photia A; Lertvivatpong N; Rujkijyanont P
    Pediatr Blood Cancer; 2021 Jun; 68(6):e29002. PubMed ID: 33754455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation.
    Osowski CL; Dix SP; Lynn M; Davidson T; Cohen L; Miyahara T; Sexauer MC; Joyce R; Yeager A; Wingard JR
    Support Care Cancer; 1998 Nov; 6(6):511-7. PubMed ID: 9833299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
    DiBenedetto J; Cubeddu LX; Ryan T; Kish JA; Sciortino D; Beall C; Eisenberg PD; Henderson C; Griffin D; Wentz A
    Clin Ther; 1995; 17(6):1091-8. PubMed ID: 8750400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
    Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
    J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women.
    Franchi M; Donadello N; Zanaboni F; Tusei A; Scorbati E
    Oncology; 1995; 52(6):509-12. PubMed ID: 7478441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
    Coiffier B; Khayat D; Misset JL; Votan B
    Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
    Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
    Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
    Hainsworth JD; Hesketh PJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.